Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document

Untitled source document

No live link available for this source.

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • SubQ dynamically selects which token relationships are important on the fly, differently for each piece of text, rather than using fixed patterns as prior sparse-attention mechanisms have done.

    60% confidence
  • SubQ is either the biggest breakthrough since the Transformer or it's AI Theranos.

    60% confidence
  • In hindsight, releasing third-party benchmarks alongside the initial announcement would have preempted the skepticism.

    60% confidence
  • The Appen evaluation validated Subquadratic's architecture and suggests SubQ could be a game changer given models' struggles with speed and inefficiency.

    60% confidence
  • Achieving competitive sparse attention is extremely difficult — akin to running a four-minute mile — and pretty much every approach under the sun has already been attempted.

    60% confidence
  • Sparse attention is justified because not all word relationships in a document are important.

    60% confidence
  • SubQ is faster, cheaper, and uses significantly less energy than any other LLM on the market.

    60% confidence
  • Subquadratic hopes to kick off a new age of LLM efficiency and believes nobody will be building on transformers in a few years.

    60% confidence
  • SubQ matches the performance of the best models from Google DeepMind, OpenAI, and Anthropic on key tasks like coding.

    60% confidence
  • It costs $2,600 to run Anthropic's Claude Opus 4.6 through the RULER 128 benchmark, versus $8 for SubQ.

    60% confidence
  • Tens of thousands of potential users have signed up for early access to SubQ, including more than 500 enterprise customers.

    60% confidence
  • SubQ scored 98% on needle-in-a-haystack with context windows of 6 million and 12 million tokens, sustaining near-perfect long-context retrieval at scales few models are tested at.

    60% confidence
  • SubQ is the first sparse-attention LLM that rivals mainstream dense-attention models in performance.

    60% confidence
  • Subquadratic may have built something real and useful, but the public evidence does not yet justify the stronger claim that they have solved the quadratic attention bottleneck.

    60% confidence
  • SubQ continues to provide frontier-level performance in coding.

    60% confidence
  • SubQ can process up to 12 times as much text at once as most other models, enabling analysis of hundreds of documents or entire codebases.

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com